INTRODUCTION

Deformity of vascular morphology and hemangioma are common in vascular diseases in clinic, more than half of which are located in the head, neck, and face. Hemangioma is also a kind of common benign subcutaneous tumor, and its most common cause is the venous distention and malformation due to abnormal embryonic development, which is generally manifested as invasive growth and medium or soft texture. The local shape and size of hemangioma can be observed by naked eyes, and the concrete depth and range of tumor invasion can be detected via such imaging methods as high-frequency ultrasound (HFU) and angiography. Common therapeutic methods for hemangioma include injection of hardening agent, local injection of hormone, chemoradiotherapy, and vascular embolization. LASERs (light amplification by stimulated emission of radiation) represent sources of high-intensity monochromatic (single wavelength) coherent light that can be used for the treatment of various dermatologic conditions depending
on the wavelength, pulse characteristics, and fluence (energy output). A dye laser employs an organic dye mixed in a solvent as the lasing medium. The dyes include rhodamine, fluorescein, coumarin, stilbene, umbelliferone, tetracene, and malachite green while the solvents used contain water, glycol, ethanol, methanol, hexane, cyclohexane, and cyclodextrin. The dye solution is usually circulated at high speeds, to promote the dye molecules into the state of being ready to emit stimulated radiation. Pulsed dye lasers produce pulses of visible light at a wavelength of 585 or 595 nm with pulse durations of the order of 0.45–40 ms, which can be combined with radiofrequency to enhance effects.5 With the constant development of laser medicine, HFU-assisted dye laser has many advantages in the treatment of hemangioma, such as small trauma and low risk of scar after treatment.6 Hemangioma not only affects the appearance, but also leads to a variety of local or systemic complications, such as ulceration, bleeding, and even infection on local surface. Hemangioma located in special sites probably results in dyspnea and diminution of vision, thus threatening the life.7 The main principle of treatment of hemangioma with HFU-assisted dye laser is the target chromophore. The target chromophore of hemangioma is the oxidized hemoglobin in blood vessels, and the laser can make oxyhemoglobin generate heat through absorbing light energy, thus causing vascular injury.8,9 With the constant development of laser medical technology, HFU-assisted dye laser has promoted the treatment of hemangioma.

### TABLE 1 Cases of different sites and types of hemangioma and age distribution

| Site                        | Type of hemangioma | Age distribution (years old) |
|-----------------------------|--------------------|-------------------------------|
|                             | Nevus flammeus     | 0-3  | 3-10 | 10-25 | >25 |
| Forehead                    | /                  | /    | /    | /     |
| Upper eyelid                | /                  | /    | /    | /     |
| Lower eyelid                | /                  | /    | /    | /     |
| Tip of nose                 | /                  | /    | /    | /     |
| Near left nose              | /                  | /    | /    | /     |
| Right cheek                 | /                  | /    | /    | /     |
| Upper lip                   | /                  | /    | /    | /     |
| Lower lip                   | /                  | /    | /    | /     |
| In front of ear             | /                  | /    | /    | /     |
| Behind ear                  | /                  | /    | /    | /     |
| Below chin                  | /                  | /    | /    | /     |
| Middle neck                 | /                  | /    | /    | /     |
| Root of neck                | /                  | /    | /    | /     |
| Upper abdomen               | /                  | /    | /    | /     |
| Waist                       | /                  | /    | /    | /     |
| Forehead                    | /                  | /    | /    | /     |
| Middle neck                 | /                  | /    | /    | /     |
| Hip                         | /                  | /    | /    | /     |
| Thenar                      | /                  | /    | /    | /     |
| Root of middle finger       | /                  | /    | /    | /     |

### 2 GENERAL MATERIALS AND METHODS

#### 2.1 General materials

A total of 20 patients diagnosed with hemangioma in our hospital from January 2013 to March 2018 were selected, including 12 males and 8 females aged 3 months to 35 years old with an average age of (17.05 ± 15.17) years old. The type and site of hemangioma and age distribution of all patients were recorded (Table 1). All patients enrolled were treated with 595 nm dye laser therapy in our hospital using the 595 nm pulsed dye laser therapeutic instrument provided by Medical Laser Company, USA. Conditions of patients were recorded before and after HFU therapy. Before treatment, all patients were informed of the mechanism, main efficacy, and possible side effects of HFU-assisted dye laser (pain during treatment, redness, swelling, and itching immediately after the procedure that may last a few days after treatment, blistering, changes in skin pigmentation, bruising a bacterial infection) and asked to be reviewed within the stipulated time after treatment. Before treatment, informed consent was obtained from patients and their families, and related files were signed.

#### 2.2 Methods

Therapeutic method: Relevant data of patients were collected before treatment, including age, gender, and site, size, scope, color, and type
of hemangioma. The hemangioma was photographed using the same camera from the same angle, light, and position and archived by the same professional physician. The skin of patients was cut to fully expose the tumor, and the surface morphology, boundary, scope, size, invasion depth, texture, and blood flow distribution in internal vessels of hemangioma were observed using the direct detection method. First, after routine surface cleaning, the local skin was disinfected, and anesthesia was not performed. Before treatment, an appropriate amount of lidocaine was applied on the focus according to the patient’s tolerance and local surface area of hemangioma, and the lidded transparent plastic magnet was pasted onto the focus for about 1 hour, followed by ultrasonic therapy. Before treatment, patients were fully informed of the related risk and curative effect. During treatment, the laser handle was always perpendicular to the focus to ensure the laser radiation to the whole treatment region, the overlapping region of light spot was approximately 10%, and the appropriate energy density was selected based on the color, size, and depth of blood vessels in hemangioma. Basically, 595 nm Venous flashlamp pulsed dye laser at a pulse duration of 0.45-40 ms, spot diameter of 4-7 mm, and energy fluence of 6.0-12.5 J/cm² was performed. The parameters of laser therapy might be slightly adjusted according to the patient’s age and type, site, and color of hemangioma. The local color changing from dark to light after radiation indicated the appropriate energy density. In case that hemangioma showed the dotted structure and could be fully overlapped, and hemangioma was located around the eye or in the eyelid, patients were asked to wear the eye shield before treatment to protect the eyes. After treatment, erythromycin ointment was applied locally, followed by sun protection, cleaning, etc. At 1 week, 2 weeks, and 1 month after treatment, patients were reviewed, and HFU detection was performed for changes in the area of hemangioma, the number of blood vessels in hemangioma, peak flow velocity ($V_{max}$) of main artery, and changes in the blood resistance index (RI).

2.3 | Statistical methods

Statistical Product and Service Solutions (SPSS) 19.0 software was used for data processing. Data were collected and expressed as ($\bar{x} \pm s$), and $t$ test was adopted for the sample mean. $P < 0.05$ suggested that the difference was statistically significant.

3 | RESULTS

3.1 | Main data of hemangioma detected via HFU before treatment

In hemangioma in different sites before treatment, there were abundant blood flow signals, a large number of blood vessels, and higher $V_{max}$ of main artery (Table 2).

3.2 | Main data of hemangioma detected via HFU at 7 days after treatment

In hemangioma in different sites at 7 days after treatment, blood flow signals weakened, and the number of blood vessels and $V_{max}$ of main artery declined compared with those before treatment (Table 3).
3.3 | Main data of hemangioma detected via HFU at 14 days after treatment

In hemangioma in different sites at 14 days after treatment, there were basically no or very weak blood flow signals, and the number of blood vessels and $V_{\text{max}}$ of main artery obviously declined (Table 4).

3.4 | Main data of hemangioma detected via HFU at 1 month after treatment

At 1 month after treatment, blood flow signals of hemangioma could be detected only in the forehead, upper abdomen, waist, and hip, while blood flow signals, blood vessels, and $V_{\text{max}}$ of main artery were not detected in other sites (Table 5).

3.5 | Changes in the area of hemangioma under HFU after treatment

Gray-scale ultrasound displayed that the area of hemangioma in different sites was reduced by more than 50%. Except 1 case of large-area hemangioma below the chin that needed longer-term follow-up or would be treated with other means eventually, the recovery of hemangioma in other sites was significant (Table 6).

3.6 | Changes in the mean percentage of decline in echo area of hemangioma under HFU after treatment

The mean percentages of decline in echo area of nevus telangiectaticus, capillary hemangioma, and cavernous hemangioma were significantly increased at 14 days after treatment compared with those at 7 days after treatment and also obviously increased at 1 month after treatment compared with those at 7 and 14 days after treatment, displaying statistically significant differences ($P < 0.05$) (Table 7).

3.7 | Changes in serum HIF-1α before and after treatment

The level of serum HIF-1α was remarkably decreased after treatment compared with that before treatment, and it was lower at 14 days after treatment than that at 7 days after treatment and also lower at 1 month after treatment than that at 7 and 14 days after treatment, showing statistically significant differences ($P < 0.05$) (Table 8).

4 | DISCUSSION

Hemangioma is a kind of vascular disease of congenital or acquired developmental anomaly of blood vessels, which is generally caused by abnormal proliferation of vascular endothelial cells and pericytes. Hemangioma can occur in any part of the body in the continuous development of disease, emerge in a kind of tissue, or invade different layers of tissues, leading to local or systemic complications. It mainly occurs in skin mucosa or oral mucosa, and cavernous hemangioma and capillary hemangioma are dominated. Cavernous hemangioma is composed of significantly enlarged vascular lumen and cavity sinus, the latter of which has

---

**TABLE 3** Main data of hemangioma detected via HFU at 7 d after treatment

| Site                  | Blood flow signal              | Number of blood vessels (n) | $V_{\text{max}}$ of main artery (m/s) | RI of main artery |
|-----------------------|--------------------------------|-----------------------------|--------------------------------------|------------------|
| Forehead              | Dendritic and lobulated shape  | 3                           | 0.23                                 | 0.45             |
| Upper eyelid          | Arteriovenous communication    | 1                           | 0.24                                 | 0.52             |
| Lower eyelid          | Single passing                 | 1                           | 0.23                                 | 0.38             |
| Tip of nose           | Single passing                 | 1                           | 0.21                                 | 0.29             |
| Near left nose        | Arteriovenous communication    | 1                           | 0.30                                 | 0.45             |
| Right cheek           | Dendritic and lobulated shape  | 2                           | 0.27                                 | 0.42             |
| Upper lip             | Arteriovenous non-communication| 1                           | 0.33                                 | 0.41             |
| Lower lip             | Arteriovenous communication    | 1                           | 0.31                                 | 0.47             |
| In front of ear       | Dendritic and lobulated shape  | 1                           | 0.25                                 | 0.37             |
| Behind ear            | Arteriovenous non-communication| 1                           | 0.24                                 | 0.38             |
| Below chin            | Arteriovenous communication    | 2                           | 0.19                                 | 0.35             |
| Middle neck           | Dendritic and lobulated shape  | 2                           | 0.20                                 | 0.32             |
| Root of neck          | Arteriovenous communication    | 1                           | 0.21                                 | 0.37             |
| Upper abdomen         | Dendritic and lobulated shape  | 2                           | 0.25                                 | 0.55             |
| Waist                 | Arteriovenous communication    | 1                           | 0.27                                 | 0.47             |
| Hip                   | Arteriovenous non-communication| 2                           | 0.29                                 | 0.32             |
| Thenar                | Arteriovenous non-communication| 1                           | 0.25                                 | 0.35             |
| Root of middle finger | Arteriovenous non-communication| 1                           | 0.30                                 | 0.30             |
### TABLE 4  Main data of hemangioma detected via HFU at 14 d after treatment

| Site                  | Blood flow signal                | Number of blood vessels (n) | $V_{\text{max}}$ of main artery (m/s) | RI of main artery |
|-----------------------|----------------------------------|----------------------------|---------------------------------------|-------------------|
| Forehead              | Dendritic and lobulated shape    | 1                          | 0.21                                  | 0.28              |
| Upper eyelid          | Arteriovenous communication      | 0                          | /                                     | /                 |
| Lower eyelid          | Single passing                   | 0                          | /                                     | /                 |
| Tip of nose           | Single passing                   | 1                          | 0.17                                  | 0.20              |
| Near left nose        | Arteriovenous communication      | 0                          | 0.19                                  | 0.30              |
| Right cheek           | Dendritic and lobulated shape    | 1                          | /                                     | /                 |
| Upper lip             | Arteriovenous non-communication  | 0                          | 0.21                                  | /                 |
| Lower lip             | Arteriovenous communication      | 0                          | /                                     | /                 |
| In front of ear       | Dendritic and lobulated shape    | 1                          | 0.18                                  | 0.29              |
| Behind ear            | Arteriovenous non-communication  | 0                          | /                                     | /                 |
| Below chin            | Arteriovenous communication      | 1                          | /                                     | /                 |
| Middle neck           | Dendritic and lobulated shape    | 0                          | 0.17                                  | 0.28              |
| Root of neck          | Arteriovenous communication      | 1                          | /                                     | 0.29              |
| Upper abdomen         | Dendritic and lobulated shape    | 0                          | 0.20                                  | 0.30              |
| Waist                 | Arteriovenous communication      | 0                          | 0.15                                  | /                 |
| Hip                   | Arteriovenous non-communication  | 1                          | 0.23                                  | /                 |
| Thenar                | Arteriovenous non-communication  | 0                          | 0.20                                  | 0.30              |
| Root of middle finger | Arteriovenous non-communication  | 0                          | 0.18                                  | 0.27              |

### TABLE 5  Main data of hemangioma detected via HFU at 1 mo after treatment

| Site                  | Blood flow signal                | Number of blood vessels (n) | $V_{\text{max}}$ of main artery (m/s) | RI of main artery |
|-----------------------|----------------------------------|----------------------------|---------------------------------------|-------------------|
| Forehead              | Single passing                   | 1                          | 0.21                                  | 0.22              |
| Upper abdomen         | Dendritic and lobulated shape    | 1                          | 0.20                                  | 0.28              |
| Waist                 | Arteriovenous communication      | 0                          | /                                     | /                 |
| Hip                   | Arteriovenous non-communication  | 1                          | 0.28                                  | 0.28              |
| Others                | /                                | /                          | /                                     | /                 |

### TABLE 6  Changes in the area of hemangioma under HFU after treatment (7, 14, and 30 d)

| Detection of changes in the area of hemangioma via HFU | 7 d after treatment | 14 d after treatment | 30 d after treatment |
|-------------------------------------------------------|---------------------|----------------------|----------------------|
| 1 case in forehead                                    | 1 case in forehead | 1 case in forehead  |
| 1 case in front of ear                                | 1 case in front of ear | 1 case in tip of nose |
| The relatively strong-echo area is reduced by 50% under HFU | 1 case in lower eyelid | 1 case below chin  |
| The relatively strong-echo area is reduced by 50%-75% under HFU |
| 2 cases                                               | 3 cases             | 23 cases             |
TABLE 7 Changes in the mean percentage of decline in echo area of hemangioma under HFU after treatment

| Time       | Nevox telangiectaticus | Capillary hemangioma | Cavernous hemangioma |
|------------|-------------------------|----------------------|----------------------|
| Before     | 253.07 ± 41.22          | 182.77 ± 50.73       | 156.23 ± 40.86       |
| 7 d after  | 109.86 ± 30.72          | 74.95 ± 25.13        | 57.12 ± 18.27        |
| 14 d after | 103.93 ± 28.11          | 69.84 ± 21.87        | 52.28 ± 16.57        |
| 30 d after | 98.04 ± 25.23           | 64.96 ± 21.02        | 50.09 ± 15.88        |

a single layer of endothelial cells, and vascular lumen and vascular sinuses are separated by connective tissues. The structure and nature of cavernous hemangioma are similar to those of sponge, and it is rich in venous blood. X-ray displays that the arteries and branches in hemangioma in the arterial phase are generally normal, hemangioma cannot be developed, but hemangioma in the venous phase can be developed, further confirming that hemangioma is derived from the vein. In the past, common therapeutic methods for hemangioma included local skin grafting, isotope therapy, local injection of hormone, and local electrocoagulation, which was less targeted, and had a therapeutic scope far beyond the focus, large trauma, and stronger inflammatory response later. In the late repair of these therapeutic methods, fibrous protein is often formed, resulting in a high risk of scar formation. With the further development of ultrasonic methods, fibrous protein is often formed, resulting in a high risk of scar formation. The severer the environmental hypoxia is, the more stable HIF-1α will be, thereby helping enhance stability and proliferation capacity of tumor cells. Some studies have demonstrated that the stronger the expression of nuclear antigen in tumor cells is, the higher the level of HIF-1α will be, the synthesis and secretion of HIF-1α are promoted by tumor cells due to hypoxia, and the level is closely related to angiogenesis.

5 | CONCLUSION

Results of this study revealed that the level of serum HIF-1α sharply declined after treatment of hemangioma with HFU-assisted dye laser, confirming the treatment effect of ultrasonic laser therapy on hemangioma.

ORCID

Jianhua Fang https://orcid.org/0000-0002-7966-7443

REFERENCES

1. Marmur ES, Berkowitz EZ, Fuchs BS, Singer GK, Yoo JY. Use of high-frequency, high-resolution ultrasound before Mohs surgery. Dermatol Surg. 2010;36(6):841-847.
2. Kleiman A, Keats EC, Chan NG, Khan ZA. Evolution of hemangioma endothelium. Exp Mol Pathol. 2012;93(2):264-272.
3. Szychta P, Stewart K, Anderson W. Treatment of infantile hemangiomas with propranolol: clinical guidelines. Plast Reconstr Surg. 2014;133(4):852-862.
4. Holland KE, Drolet BA. Infantile hemangioma. Pediatr Clin North Am. 2010;57(5):1069-1083.
5. Nagore E, Requena C, Sevila A, et al. Thickness of healthy and affected skin of children with port wine stains: potential repercussions on response to pulsed dye laser treatment. Dermatol Surg. 2004;30(12 Pt 1):1457-1461.
6. George A, Mani V, Noufal A. Update on the classification of hemangioma. J Oral Maxillofac Pathol. 2014;18(4):117-120.
7. Choi J, Im SA, Kim JY. Submucosal Hemangioma of the Trachea in an Infant: Diagnosis and Follow-Up with 3DCT /Bronchoscopy. Iran J Pediatr. 2016;26(1):e2346.
8. Khan SN, Sepahdari AR. Orbital masses: CT and MRI of common vascular lesions, benign tumors, and malignancies. Saudi J Ophthalmol. 2012;26(4):373-383.
9. Spierer O, Neudorfer M, Leibovitch I, Stolovitch C, Kessler A. Colour Doppler ultrasound imaging findings in paediatric periocular and orbital haemangiomas. Acta Ophthalmol. 2012;90(8):727-732.
10. Griauzde J, Srinivasan A. Imaging of vascular lesions of the head and neck. Radiol Clin North Am. 2015;53(1):197-213.
11. Yan X, Li MU, Chen Z, Zhu Y, Song Y, Zhang H. Schlemm’s canal and trabecular meshwork in eyes with primary open angle glaucoma: a comparative study using high-frequency ultrasound biomicroscopy. PLoS ONE. 2016;11(1):e0145824.
12. Unsal E, Eltutar K, Muftuoglu I. Biomicroscopy in patients with unilateral pseudoexfoliation. Int. J Ophthalmol. 2015;8(4):754-758.
13. Shi H, Song H, Wang J, et al. Ultrasound in assessing the efficacy of propranolol therapy for infantile hemangiomas. Ultrasound Med Biol. 2014;40(11):2622-2629.
14. Kutz AM, Aranibar L, Lobos N, Wortsman X. Color Doppler ultrasound follow-up of infantile hemangiomas and peripheral vascularity in patients treated with propranolol. Pediatr Dermatol. 2015;32(4):468-475.
15. Ranieri G, Marech I, Lorusso V. Molecular targeting agents associated with transarterial chemoembolization or radiofrequency ablation in hepatocarcinoma treatment. World. J Gastroenterol. 2014;20(2):486.
16. Kong W-D, Cao J-M, Xu J, et al. Impact of low versus conventional doses of chemotherapy during transcatheter arterial chemoembolization on serum fibrosis indicators and survival of liver cancer patients. Asian Pac J Cancer Prev. 2012;13(9):4757-4761.
17. Cui L, Liu X-X, Jiang Y, et al. Comparative study on transcatheter arterial chemoembolization, portal vein embolization and high intensity focused ultrasound sequential therapy for patients. Asian Pac J Cancer Prev. 2012;13(12):6257-6261.
18. Goertz R, Zopf Y, Jugl V, et al. Measurement of liver elasticity with acoustic radiation force impulse (ARFI) technology: an alternative noninvasive method for staging liver fibrosis in viral hepatitis. Ultraschall Med. 2010;31(2):151-155.
19. Rizzo C, Brightman L, Chapas AM, et al. Outcomes of childhood hemangiomas treated with the pulsed-dye laser with dynamic cooling: A retrospective chart analysis. Dermatol Surg. 2009;35(12):1947-1954.
20. Chaudhari MH, Forsberg F, Voodarla A, et al. Breast tumor vascularity identified by contrast enhanced ultrasound and pathology: initial results. Ultrasonics. 2000;38(1-8):105-109.
21. Xu JM, Guo LH, Xu HK. Differential diagnosis of gallbladder wall thickening: the usefulness of contrast-enhanced ultrasound. Ultrasound Med Biol. 2014;40(12):2794-2804.

How to cite this article: Hu H, Song P, Yang J, Wang X, Chen Z, Fang J. Therapeutic effect of high-frequency ultrasound-assisted dye laser on hemangioma and its influence on serum HIF-1α in patients. J Clin Lab Anal. 2020;34:e22970. https://doi.org/10.1002/jcla.22970